Reseda, CA, United States of America

Tove Olafsen

USPTO Granted Patents = 10 

 

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 71(Granted Patents)


Company Filing History:


Years Active: 2014-2025

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents

Title: Tove Olafsen: Innovator in Antigen Binding Constructs

Introduction

Tove Olafsen is a prominent inventor based in Reseda, CA (US). She has made significant contributions to the field of biotechnology, particularly in the development of antigen binding constructs. With a total of 10 patents to her name, Olafsen's work has the potential to impact various therapeutic applications.

Latest Patents

Among her latest patents are innovative constructs that bind to CD8 and CD4. The patent for antigen binding constructs to CD8 describes antibodies, including fragments such as scFv, minibodies, and cys-diabodies, that specifically target CD8. Additionally, her patent for antigen binding constructs to CD4 outlines similar constructs that bind to CD4, along with methods of use for these antibodies.

Career Highlights

Tove Olafsen has established herself as a key figure in her field through her work at Imaginab, Inc. Her research focuses on advancing the understanding and application of antigen binding technologies. Her contributions have been recognized within the scientific community, showcasing her expertise and innovative spirit.

Collaborations

Olafsen has collaborated with notable professionals in her field, including David T. Ho and Christian P. Behrenbruch. These collaborations have further enhanced her research and development efforts, leading to groundbreaking advancements in biotechnology.

Conclusion

Tove Olafsen's work in antigen binding constructs exemplifies her dedication to innovation in biotechnology. Her patents and collaborations highlight her significant contributions to the field, paving the way for future advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…